OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Musculoskeletal Disease is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis	103
Erratum to “Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feas	57
The impact of psoriatic arthritis on quality of life: a systematic review	33
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients	31
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review	25
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers	22
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis	22
Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study	21
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France	20
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib	19
Dispositional traits help explain individual differences in relationships between a radiographic knee osteoarthritis measure, pain, and physical function	19
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis	18
Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage	18
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series	18
Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1)	18
Back pain treatment: a new perspective	17
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment	16
Regenerative medicine for early osteoarthritis	15
Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up	15
Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure	15
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance	14
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease	14
Acute effects of exercise on pain symptoms, clinical inflammatory markers and inflammatory cytokines in people with rheumatoid arthritis: a systematic literature review	14
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome	13
MRI lesions in SpA: a comparison with noninflammatory back pain using propensity score adjustment method	13

Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis	13
Fracture in clinical studies of tofacitinib in rheumatoid arthritis	12
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study	12
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study	12
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis	12
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)	12
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients	11
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry	11
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus	11
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review	11
Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients	11
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI	11
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data	10
The interplay between dysregulated metabolites and signaling pathway alterations involved in osteoarthritis: a systematic review	10
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice	10
Imaging in psoriatic arthritis: established methods and emerging techniques	10
Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort	10
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic	10
Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis	10
Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence	9
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2	9
SCORE2 is superior to SCORE in predicting the presence of carotid plaques and intima-media thickness in rheumatoid arthritis patients: a cross-sectional study using carotid ultrasound	9
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review	9
Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity	9
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge	9
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort	8
A glance into the future of gout	8
Retraction notice	8
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)	7
Precision medicine using molecular-target drugs in psoriatic arthritis	7
Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol	7
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthri	7
SCORE2 versus SCORE in patients with systemic lupus erythematosus	7
The analysis of the pulmonary domain involvement in Sjögren’s disease	7
New insights on multigenic autoinflammatory diseases	7
A broad look into the future of rheumatoid arthritis	7
Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials	7
Infections in psoriatic arthritis: association with treatment	6
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients	6
Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients	6
Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested case–control study	6
Artificial intelligence in rheumatology: status quo and quo vadis—results of a national survey among German rheumatologists	6
Precision medicine in axial spondyloarthritis: current opportunities and future perspectives	6
Comparison of clinical efficiency between intra-articular injection of platelet-rich plasma and hyaluronic acid for osteoarthritis: a meta-analysis of randomized controlled trials	6
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy	5
Oral enzyme combination with bromelain, trypsin and the flavonoid rutoside reduces systemic inflammation and pain when used pre- and post-operatively in elective total hip replacement: a randomized ex	5
Risk factors and prognosis of depression in Takayasu arteritis patients	5
Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis	5
Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study	5
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs	5

Latest insights in disease-modifying osteoarthritis drugs development	5
New insights in lower limb reconstruction strategies	5
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry	5
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids	5
The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic	4
Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients	4
Racial and ethnic differences in the pharmacologic management of osteoarthritis: rapid systematic review	4
Effectiveness and safety of immunoadsorption as a rescue treatment of inflammatory myopathies: report of three cases and literature review	4
Mapping two decades of research in rheumatology-specific journals: a topic modeling analysis with BERTopic	4
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies	4
SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD	4
A broad look into the future of systemic sclerosis	4
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors	4
Uveitis in peripheral spondyloarthritis patients: an ancillary analysis of the ASAS-PerSpA study	4
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials	4
Relationship between onset of psoriasis and spondyloarthritis symptoms with clinical phenotype and diagnosis: data from REGISPONSER registry	4
Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis	4
Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose	4
Predicting osteoarthritis in adults using statistical data mining and machine learning	4
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes	4
Cost-effectiveness of specialised manual therapy versus orthopaedic care for musculoskeletal disorders: long-term follow-up and health economic model	3
Calcineurin inhibitors in systemic sclerosis – a systematic literature review	3
Selection of X-ray versus magnetic resonance imaging as a first-line imaging modality for diagnosing axial spondyloarthritis	3
Gout management and outcomes during established COVID-19 pandemic in 2020–2021: a cross-sectional Internet survey	3
Neuro-PIMS-TS: a single case report and review of the literature	3
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?	3
Osteosarcopenia and Long-COVID: a dangerous combination	3
The signature of the gut microbiota associated with psoriatic arthritis revealed by metagenomics	3
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study	3
A glance into the future of diagnosis and treatment of spondyloarthritis	3
Characterization of missing data patterns and mechanisms in longitudinal composite outcome trial in rheumatoid arthritis	3
Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy	3
Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exp	3
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on ‘Diagnosis, risk stratification, and continuity of care of fragility fractures’ based on a systematic	3
The association between gout flares and monosodium urate burden assessed using musculoskeletal ultrasound in patients with gout	3
A glance into the future of myositis therapy	3
Health disparities in rheumatoid arthritis	3